BioSpace News Archive

Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies (VNARs) directed against the SARS-CoV-2 spike protein.

Senda Biosciences, announced today the completion of a $55 million Series B extension financing, bringing its total Series B funding to $98 million and total funding raised to date to $143 million

Semler Scientific, Inc. announced that its chief executive officer, Doug Murphy-Chutorian, and chief marketing officer, Dennis Rosenberg, will present a company overview at the Raymond James Human Health Innovation Conference on Tuesday, June 22, at 12:00 pm ET.

Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ Engine (AiCE), Canon Medical Systems USA Inc.’s Deep Learning Reconstruction (DLR) technology, is now 510(k) cleared on the Cartesion Prime Digital PET/CT system and will be showcased at SNMMI 2021 for both PET and CT acquisitions.

Monte Rosa Therapeutics announced today the appointment of Filip Janku, M.D., Ph.D., as the company’s first chief medical officer.

The Wyss Institute for Biologically Inspired Engineering at Harvard University announces that it is collaborating with multiple industry partners to discover more effective approaches to deliver drugs across the blood-brain barrier for the treatment of brain diseases.

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2021.

Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, announced the appointment of Kathy Yi, Chief Financial Officer of Cerevel Therapeutics, to its Board of Directors, where she will serve as Chair of the Audit Committee.

Seres Therapeutics, Inc. announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.

Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2021 on Wednesday, July 28, 2021. During a conference call at 8 a.m. ET on July 28, 2021.